Beamtree Holdings Ltd · ASX:BMT
Beamtree — FY2025 Earnings Presentation
22 slides from Beamtree's earnings presentation, Aug 28, 2025
Slide 1: FY25 Audited Annual Results
FY25 FY25 Audited Annual Results 28 August 2025 Authorised for release by the Board of Directors
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer The material in this presentation is general background information about Beamtree Holdings Limited (ASX:BMT) and is current at the date of the presentation, August 2025. This presentation may contain statements that are, or may be deemed to be, forward looking statem
Slide 3: FY25 Highlights
Beamtree FY25 Highlights
Slide 4: FY25 Financial Highlights
FY25 Financial Highlights 15% 4% 78% 220% $4.8M PCP* PCP PCP PCP Annual recurring Reported Revenue Operating Profit Operating Cash Revenue Cashflow $29.2M $28.6M $0.7M $0.6M ~Balance excludes undrawn debt facility of NZ$5M Strong Q4 momentum (87% recurring) Strong Q4 **Prior Corresponding Period “PC
Slide 5: FY25 Highlights
FY25 Highlights • New CEO appointed 12 March 2025. Resetting of priorities underway including improved sales pipeline disciplines and streamlin ed product development pipeline. • ARR growth of 15% for FY25 driven by Q4 ARR growth of 12% QoQ. Q4 also delivered record recurring revenue and operating p
Slide 6: Q4 FY25 Sales Pipeline Conversion + 1H FY26 Pipeline
Q4 FY25 Sales Pipeline Conversion + 1H FY26 Pipeline April 25 Q4 Target Actual Q4 Conversion + IH Pipeline Q4 Pipeline Commentary PICQ 0.9m PICQ 1.5m Strong PICQ Audit demand with 1/3rd of PICQ customers signed up. Autonomous Coding 0.8m Autonomous Coding 0.0m 3 ACS programs underway, revenue $0.6m;
Slide 7: Who we are
Beamtree Who we are
Slide 8: Beamtree
Beamtree Beamtree is Australia’s market leading tech company focused on innovative AI enhanced solutions for coded data in the hospital and pathology markets Who we are We have deep expertise in Hospital clinical data coding (25% of revenue) Unique Australian IP +20 years experience Hospital and hea
Slide 9: Our Markets and Partners
Our Markets and Partners United Kingdom ~5 Core countries Canada • 68m population • 39m population ~300 Customers Saudia Arabia • 38m population +1200 Locations Australia • 27m population 3 partners New Zealand • 5m population Copyright © Beamtree Holdings Limited – All Rights Reserved 8
Slide 10: We deliver ten products to healthcare clients across three segments
We deliver ten products to healthcare clients across three segments Segment Our products What we deliver: Our clients • Autonomous Coding Software that makes clinical coding more efficient by System (ACS) saving time for human clinical coders (ICP), and Hospitals • Integrated Coding Platform automat
Slide 11: Beamtree's pathway to advanced coding solutions
Beamtree’s pathway to advanced coding solutions Coding Quality Assisted Coding Autonomous Coding PICQ & RISQ Integrated Coding Platform (“ICP”) (“ACS”) Current Products New Product Going Live Programs Underway in 3 Countries Supports human coder in the end-to-end “No touch” coding solution that can
Slide 12: We are on a multi-year journey to become a leader in clinical coding
We are on a multi-year journey to become a leader in clinical coding FY26 FY27 – FY28 FY29+ Further develop our coding Embed best in class Become the preferred 'one products in market, and technology into coding stop shop' provider for define organisation products and scale them clinical coding stru
Slide 13: FY25 Financial Results
Beamtree FY25 Financial Results
Slide 14: Profit and Loss
Profit and Loss FY23 FY24 FY25 FY25 Growth Annual Recurring Revenue 22.8 25.5 29.2 15% Diagnostics 6.0 6.8 7.5 10 % ARR Growth Coding & Data Quality Assurance Clinical Decision Support Knowledge Networks 4.4 0 .6 10 .1 5.3 0 .4 10 .8 5.9 0 .5 11.1 13% 7% 3% +15% Total Recurring Revenue 21.2 23.3 25.
Slide 15: Track Record of Revenue Growth
Track Record of Revenue Growth ($’M) ARR Value 6.7 18.2 22.8 25.5 29.2 ARR Growth +172% +25% +12% +15% 28.6 27.6 22.8 10.7 39% 12.9 45% International Revenue Australia Revenue 7.3 32% 16.5 4.1 25% 8.4 16.9 61% 15.5 68% 15.7 55% 3.6 43% 12.4 75% 4.8 57% FY21 +97% FY22 +38% FY23 +21% FY24 +4% FY25 Cop
Slide 16: Controlled Operating Expense Growth
Controlled Operating Expense Growth ($’M) Non-employment Employment FY21 FY22 FY23 FY24 FY25 63% (4.7) 37% (2.8) 69% (14.2) 72% +5% YoY (7.5) (17.3) 72% (19.7) 74% (20.6) (6.3) 31% (6.9) 28% (20.6) -3% YoY (7.5) 28% (7.3) 26% +85% (24.2) +7%* (27.2) (27.9) +12% +2% * Organic growth levels 15 Copyrig
Slide 17: Reported EBITDA
Reported EBITDA Operating Profit to EBITDA Reconciliation FY25 saw another significant improvement in financial performance FY23 FY24 FY25 Operating Profit (1.4) 0.4 0.7 Non-Operating Expenses (Cash) Restructuring & Other Non-Operating Costs (0.4) (0.1) (0.4) Annual Operating Profit Trend Impact of
Slide 18: Cashflow
Cashflow FY23 FY24 FY25 Operating Activities Receipts from Customers (inc. GST) 25.4 30.9 31.7 Strong operating Payments to Suppliers & Employees (inc. GST) (25.4) (31.5) (31.1) cashflow in 2H Interest Received 0.0 0.1 0.0 2H FY25 +$0.6m vs $0m in 1H FY25 Interest & Finance Costs Paid (0.0) (0.0) (0
Slide 19: Balance Sheet
Balance Sheet FY23 FY24 FY25 Current Assets Cash & Cash Equivalents Trade & Other Receivables 8.8 5.3 5.0 6.3 4.8 4.7 Strong Cash Position $4.8m Contract Assets 0.3 0.2 0.1 Total Current Assets 14.4 11.5 9.6 Non-Current Assets Property, Plant & Equipment 0.3 0.2 0.2 Right-of-Use Assets 0.2 1.2 0.9 I
Slide 20: FY26 Outlook
Beamtree FY26 Outlook
Slide 21: FY26 Outlook
FY26 Outlook Product Priorities: Financial: 1. Autonomous Coding Solution: Complete 1. Q4 record ARR growth, Q1 momentum combined programs in Canada, UK and Australia Develop with relentless cost management, gives the Board minimum viable product for scale. and Management confidence of ongoing impro
Slide 22: Thank you
Thank you 21